MedTrace Logo

Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow

NCT03551951 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 320

Last updated 2025-10-08

No results posted yet for this study

Summary

Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Also, early detection of lung cancer with low dose CT screening may cure patients at an early stage. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized therapies and improve screening.

Conditions

Interventions

DIAGNOSTIC_TEST

Test for circulating tumor cells, DNA alterations

Sponsors & Collaborators

  • Harry S. Truman Memorial Veterans' Hospital

    collaborator FED

  • University of Missouri-Columbia

    lead OTHER

Principal Investigators

  • Jussuf T Kaifi, MD · University of Missouri Health Care

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-01
Primary Completion
2027-12-30
Completion
2027-12-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03551951 on ClinicalTrials.gov